
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KV23a
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : GEM Global Yield
Deal Size : $120.0 million
Deal Type : Financing
Kensana Lands $120 Million from GEM, Fuelling a Global Plant Based Medicine Revolution
Details : The proceeds will be used to advance the clinical development of its lead botanical candidate KV23A, which is being positioned to enter a registerable Phase 3 program.
Product Name : KV23a
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
September 19, 2025
Lead Product(s) : KV23a
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : GEM Global Yield
Deal Size : $120.0 million
Deal Type : Financing
